Puma Biotechnology Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Puma Biotech (PBYI) Tops Q2 EPS by 65c, Revenues Miss
August 6, 2020 5:53 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.35, $0.65 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $48.8 million versus the consensus estimate of $58.21 million.
We are pleased to announce that despite the challenges presented by the COVID-19 situation as well as a significant inventory draw down by specialty pharmacies in the quarter, we were able to... More
